Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | SLC6A9 | P48067 | 16/20 | 0.58 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4147771 | 0.87 | SLC6A9 (0.56) | LMNASLC6A9SLC6A5KCNH2MAPT | |
| SCHEMBL29378266 | 0.83 | GPR119 (0.68) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL355131 | 0.83 | GPR119 (0.68) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL248276 | 0.83 | LMNA (0.52) | LMNASLC6A9SLC6A5KCNH2 | |
| SCHEMBL22914752 | 0.83 | LMNA (0.47) | LMNASLC6A9SLC6A5KCNH2ALDH1A1 | |
| SCHEMBL18711276 | 0.81 | TP53 (0.56) | LMNAMAPTKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6679416 | 0.81 | ALDH1A1 (0.57) | SLC6A9SLC6A5KCNH2MAPTALDH1A1 | |
| SCHEMBL2329500 | 0.80 | LMNA (0.52) | LMNASLC6A9SLC6A5MAPTMAPK1 | |
| SCHEMBL13419194 | 0.80 | MAPT (0.54) | LMNAMAPTHTTKMT2ASMN1; SMN2 | |
| SCHEMBL31485198 | 0.78 | ALDH1A1 (0.64) | LMNASLC6A5MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001863-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INT (DE) | 2026-01-01 | — | — | US | disclosed |
| CN-118666853-A | N-methyl N- (6- (methoxy) pyridazin-3-yl) amine derivatives for the treatment of inflammatory airway diseases or fibrotic diseases | 勃林格殷格翰国际有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-114206876-B | N-methyl, N- (6- (methoxy) pyridazin-3-yl) amine derivatives as modulators of Autotaxin (ATX) for the treatment of inflammatory airway diseases or fibrotic diseases | 勃林格殷格翰国际有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4364805-A2 | NOVEL PYRIDAZINES | Boehringer Ingelheim International GmbH (DE) | 2024-05-08 | — | — | EP | disclosed |
| EP-4003999-B1 | 1-(6-(METHOXY)PYRIDAZIN-3-YL)CYCLOPROPANE-1-CARBOXAMIDE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2024-05-01 | — | — | EP | disclosed |
| CN-114206871-B | 1- (6- (methoxy) pyridazin-3-yl) cyclopropane-1-carboxamide derivatives as modulators of Autotaxin (ATX) for the treatment of inflammatory airway diseases | 勃林格殷格翰国际有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4003998-B1 | N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2024-03-27 | — | — | EP | disclosed |
| US-20230100516-A1 | PYRIDAZINES | BOEHRINGER INGELHEIM INT (DE) | 2023-03-30 | — | — | US | disclosed |
| US-20230022770-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230022770-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-11485727-B2 | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-11-01 | — | — | US | disclosed |
| US-11465982-B2 | Pyridazines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-10-11 | — | — | US | disclosed |
| CN-114206871-A | 1- (6- (methoxy) pyridazin-3-yl) cyclopropane-1-carboxamide derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway diseases | 勃林格殷格翰国际有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114206876-A | N-methyl, N- (6- (methoxy) pyridazin-3-yl) amine derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway diseases or fibrotic diseases | 勃林格殷格翰国际有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20210024492-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| US-20210024495-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| US-20210024492-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| US-20210024495-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| WO-2021013830-A1 | N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021013832-A1 | 1-(6-(METHOXY)PYRIDAZIN-3-YL)CYCLOPROPANE-1-CARBOXAMIDE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11465982-B2 | Pyridazines | ENPP2, PLPBP, PRDX5 | LMNA 1181/4885SLC6A9 4805/4885SLC6A5 3899/4885 |
| US-20210024492-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | LMNA 1587/4885SLC6A9 4834/4885SLC6A5 4156/4885 |
| US-20230100516-A1 | PYRIDAZINES | ENPP2, PLPBP, PRDX5 | LMNA 1238/4885SLC6A9 4827/4885SLC6A5 3927/4885 |
| US-20260001863-A1 | NOVEL PYRIDAZINES | ENPP2, LPAR5, LPAR1 | LMNA 1037/4885SLC6A9 4640/4885SLC6A5 4033/4885 |
| US-20210024495-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | LMNA 1587/4885SLC6A9 4834/4885SLC6A5 4156/4885 |
| US-20230022770-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | LMNA 1587/4885SLC6A9 4834/4885SLC6A5 4156/4885 |
| US-11485727-B2 | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators | ENPP2, ATXN10, ATXN2L | LMNA 403/4885SLC6A9 4429/4885SLC6A5 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.